GSK splashes up to $750m on experimental cancer therapy
Yahoo · 15 de sept de 2026
GSK PLC (LSE:GSK, NYSE:GSK) has agreed to pay up to $750 million for an experimental cancer therapy from the privately owned Chinese biotech Chimagen Bioscience…
CEDEAR GSK
GSK Plc.
Sí, existe CEDEAR de GSK en Argentina. Operás bajo el ticker GSK en BYMA, con ratio 4:1 respecto a la acción en NYSE.
Empresa subyacente
HealthcareDrug Manufacturers - General
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus. Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions. It also focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. It has a collaboration agreement with CureVac to develop mRNA vaccines for infectious diseases; and strategic research collaboration with Engitix Ltd. to identify and validate novel therapeutic targets driving liver fibrosis regression. The company has a strategic alliance with AN2 Therapeutics, Inc. for the development of new therapies for TB. GSK plc was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. The company was founded in 1715 and is headquartered in London, United Kingdom.
- País
- United Kingdom
- Empleados
- 66.841
- Sitio web
- gsk.com
Precio histórico
Últimos 203 días · 12/11/25 — 14/09/26
+12.25%
Cotización y datos
NYSERatio 4:1 · Subyacente GSK
CEDEAR (ARS)
Precio
$ 19.960
Var. %
-0,05%
Volumen operado
4.093
Subyacente (USD)
Precio GSK
US$ 50,06
Teórico (precio / ratio)
GSK ÷ 4
US$ 12,51
Dólar MEP (GSKD)
Preguntas frecuentes
¿Existe CEDEAR de GSK en Argentina?
Sí, existe el CEDEAR de GSK (GSK Plc.) en la Bolsa de Comercio de Buenos Aires (BYMA). Su ticker local es GSK.
¿Cuál es el ticker del CEDEAR de GSK Plc.?
El ticker del CEDEAR de GSK Plc. en Argentina es GSK. La acción subyacente cotiza en NYSE con el símbolo GSK.
¿Cuál es el ratio del CEDEAR GSK?
El CEDEAR GSK tiene un ratio de 4:1. Eso significa que 4 CEDEARs equivalen a 1 acción de GSK.
¿Cuánto vale el CEDEAR GSK hoy?
El CEDEAR GSK cotiza hoy a $ 19.960 en pesos argentinos, con una variación diaria de -0,05%.
¿Cuánto vale la acción GSK en dólares?
La acción subyacente GSK (GSK Plc.) cotiza a US$ 50,06 en su mercado de origen (NYSE).
Noticias
Finding Value Opportunities Among Highly Rated Stocks
SeekingAlpha · 14 de sept de 2026
U.S. equity markets moved lower this week, with broad weakness across most major ETFs and sector benchmarks.
INCY Stock Gains 23% Year to Date: Buy, Sell or Hold?
Yahoo · 14 de sept de 2026
Incyte's strong product demand and pipeline progress fuel its 23% YTD rally, but valuation and near-term earnings pressure temper the outlook.